Project Grant SB1AR084380
Award Date
8/6/24
Completion Date
7/31/27
Dollars Obligated
$505K
Awardee
Ortholevo, Inc. (P3HTBAK4HNC4)
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Lexington, MA 02421, USA
Similar Awards
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Panorama Research Incorporated, doing business as Panorama Research Inc., a $275,765 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to develop an antibody-based therapy for reducing scarring and fibrosis following joint surgeries. The project aims to improve the delivery and tissue residence of a lead humanized antibody that inhibits collagen fibril formation, thereby...
This Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a relaxin-loaded hydrogel for the treatment of hypertrophic scars. The $526,041 award to Trustees of Boston University will fund research to: 1) determine the mechanism of action of relaxin-2 in reducing fibrotic scarring in vitro and ex vvivo, 2) develop a hydrogel...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,924 to Biotherapeutics, Inc. to advance the development of a novel oral, first-in-class therapeutic for the treatment of rheumatoid arthritis (RA). The project aims to conduct pharmacokinetic and safety studies, characterize the effects of the lead compound on human fibroblast-like...
This Project Grant award of $680,325 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research aimed at understanding the critical mechanisms of collagen proteostasis and assessing the therapeutic potential of proteostasis network-targeted interventions for the treatment of collagenopathies. The key products and services to be delivered under this 5-year award...
This $295,481 Project Grant awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) aims to develop and validate a novel multifunctional colloidal scaffold called "MuscleInk" for the treatment of volumetric muscle loss (VML). MuscleInk is a gelatin-methacryloyl-based porous scaffold that can be crosslinked in situ and is impregnated with insulin-like growth...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel therapeutic agent called M10 for treating skin fibrosis associated with systemic sclerosis (scleroderma). The $613,036 award will enable Fibrobiologics LLC, a for-profit biotechnology research firm, to conduct preclinical research over a 12-month period...
This Project Grant award with Federal Grant ID R21AR082992 was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The $752,620 grant supports the development of injectable, cell-adhesive alginate hydrogels containing insulin-like growth factor 1 (IGF-1) mimicking peptides. The goal is to enhance the therapeutic potential of mesenchymal stem cells (MSCs) for repairing...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to define the efficacy of pharmacologically activating the G-protein coupled receptor GPR68 to modulate the dynamics of tenocyte-myofibroblast interactions during fibrotic tendon healing. The $203,280 award, running from August 2024 to May 2026, will support research at the University of...
This $468,769 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846) will support research to identify optimal physical therapy and anti-inflammatory biological intervention strategies to reduce post-traumatic joint contracture (PTJC) following joint injury. The research, conducted by The Washington University in St. Louis, will use a preclinical animal model to determine the parameters of active physical therapy, including initiation,...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $241,778 to Polymerix Technologies LLC to develop an improved process for manufacturing crosslinked ultra-high molecular weight polyethylene (UHMWPE) components for joint replacement implants. The key objectives are to optimize a pressure-quenching process to enhance the mechanical...